GoCART clinical case discussion series on CART

Do you want to join on 16th November at 4 pm CEST, please register here to join this free activity!

The GoCART Coalition, it’s cofounders EBMT and EHA, together with King Faisal Hospital Riyadh are organising a series of educational clinical case discussions on CAR T-cell therapies. In each meeting we will present and discuss 2 cases to help meeting participants gain from the experiences of experts in the field!

After the first two successful GoCART Clinical Case Discussions on CAR T-cells it is our great pleasure to invite you to the next meeting that will take place on 16th November from 4-5 pm CET. The meeting will be hosted by Dr. Osman Ahmed and Dr. Julio Delgado, Prof. Dr. Monique Minnema and Prof. Dr. Martin Dreyling as our panel experts! 

We will be discussing two real-life clinical cases as instructive examples of CAR T-cell treatments, toxicity management and outcomes. Our previous meetings have shown that the Clinical Case Discussion series are valuable to trainees as well as established physicians. “From paper to the exciting and sometimes difficult reality of CAR T cells, please join our GoCART expert panel meeting for practical insights.” 

Click here to download the template if you would like to submit your case. If you would like to submit a case to be discussed, please contact Yolanda Cabrerizo (y.cabrerizo@ehaweb.org) or Sofie Terwel (sofie.terwel@ebmt.org).

Next meeting will take place via Webex on the 16th of November from 4 until 5pm CEST and Drs. Julio Delgado, Martin Dreyling and Monique Minnema will be our panel experts.

 PLEASE click register/fill/submit in this link below to be able to join the 16th Nov  the Webex call (we will NOT use Teams environment from now on!!!)

https://ebmt.webex.com/ebmt/onstage/g.php?MTID=e1e3808b2a81d1bda4242e84797cc0580

Osman Ahmed (King Faisal Specialist Hospital and Research Center, Riyadh) acquired his medical qualifications from Imperial College,  London and subsequently trained in Medicine and Haematology. Since 2012, he has been a consultant at the King Faisal Specialist Hospital in Riyadh. His main interests are AML and transplantation, and is the Adult CAR T-cell lead at the institution.


Julio Delgado (Hospital Clínic Barcelona) is a consultant haematologist at Hospital Clínic, Barcelona, researcher at IDIBAPS, and associate professor at the University of Barcelona. He is the PI of the CART19-BE-01 trial, evaluating the role of CART19 cells in B-cell malignancies, and advisor to the EMA and the AEMPS.


Monique Minnema (UMC Utrecht) is specialized in the diagnosis and treatment of B cell malignancies, especially plasma cell dyscrasias, like Multiple Myeloma, AL amyloidosis, and Waldenström’s Macroglobulinemia. She initiated and supervises the hematology clinical research team, which coordinates and supports all clinical studies at the department of Hematology. Her main focus of clinical research is the development of novel therapies (both cellular and drug) for plasma cell dyscrasias and lymphoma. In 2019, 2020 and 2021 she organized the first Dutch symposia on “Innovations in Cellular Therapy”.


Martin Dreyling (LMU Hospital Munich) is Professor of Medicine and head of the lymphoma programme in the Department of Medicine III, LMU Hospital, Munich. His scientific focus is on the molecular prognostic factors in malignant lymphoma. He is especially interested in innovative therapeutic approaches like inhibitors of the B-cell receptor pathway and immunological approaches.

Learning objectives

  • Discuss real-life clinical cases as instructive examples
    • Get indication of the decision-making process
    • Foster lateral thinking to participant’s own cases
    • Contribute to a broader understanding of CAR T-cell treatments, toxicity management and outcomes
    • Help established physicians as well as trainees to improve patient care
  • Programme
15:50-16:00Access time to the virtual meeting
16:00-16:05Welcome to the meeting participants by Osman Ahmed
16:05-16:12Presentation case 1 
16:13-16:301 or 2 polling questions / Panel discussion / Questions from meeting participants
16:30-16:37Presentation case 2
16:38-16:551 or 2 polling questions / Panel discussion / Questions from meeting participants
16:56-17:00Closing remarks including notification next meeting